Reported 1 day ago
Jim Cramer discussed the challenges faced by Moderna, Inc. (MRNA), highlighting a significant 38% year-to-date drop in share value due to declining demand for its mRNA vaccines. The company revised its revenue expectations downward, primarily owing to deferred COVID vaccine revenue. Cramer called it a 'double whammy,' indicating issues with vaccine perception and market trust.
Source: YAHOO